Compare Enveric Biosciences Inc (ENVB) vs Essex Property Trust, Inc. (ESS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Essex Property Trust, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Essex Property Trust, Inc. trades at $269.13 (market cap $17.23B). The key difference: Essex Property Trust, Inc. is far larger — about 2575.5× Enveric Biosciences Inc's market cap, and Essex Property Trust, Inc. pays a 3.86% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Essex Property Trust, Inc. for 111 Days on average.
| ENVB | ESS | |
|---|---|---|
Market Cap | $6.69M | $17.23B |
Volume | 41,141 | 346,109 |
Sector | Health | Real Estate |
52-Week High | $10.80 | $298.33 |
52-Week Low | $1.27 | $239.61 |
Typical Hold Time | 14 Days | 111 Days |
Enterprise Value | -$1.60M | $23.82B |
Dividend Yield | — | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
ESS trades at $268.05, down 1.63% with bearish technical signals. The company reported mixed Q2 2026 results, beating FFO estimates but missing EPS expectations. Strong operational performance and litigation resolution provide fundamental support, though high valuation ratios and debt levels present concerns. Recent institutional buying and a $2.59 dividend declaration highlight investor confidence.
Outlook remains cautiously optimistic with a $303.41 consensus price target offering 13% upside. Key risks include earnings volatility, high leverage, and regional economic exposure. The stock presents a balanced opportunity for income-focused investors seeking quality REIT exposure with disciplined risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →
